Stock Events

Stock Events

Gilead Sciences 

$133.48
2786
+$0.75+0.56% Tuesday 20:00

Statistics

Day High
133.98
Day Low
131.89
52W High
155.8
52W Low
96.91
Volume
5,957,306
Avg. Volume
-
Mkt Cap
165.7B
P/E Ratio
19.42
Dividend Yield
2.46%
Dividend
3.28

Upcoming

15
JUN
Dividend Ex
Estimated
 
26
JUN
Dividend Payment
Estimated
 
15
SEP
Dividend Ex
Estimated
 
29
SEP
Dividend Payment
Estimated
 
15
DEC
Dividend Ex
Estimated
 

Dividends

2.46%Dividend Yield
Mar 26
$0.82
Dec 25
$0.79
Sep 25
$0.79
Jun 25
$0.79
Mar 25
$0.79
10Y Growth
5.95%
5Y Growth
2.92%
3Y Growth
3.02%
1Y Growth
3.8%

Earnings

7MayExpected
Q2 2024
Q4 2024
Q4 2024
Q2 2025
Q2 2025
Q4 2025
Next
1.74
1.83
1.92
2.01
Expected EPS
1.909476
Actual EPS
N/A

Financials

28.9%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
58.89BRevenue
17.02BNet Income

Analyst Ratings

160.64Average Price Target
The highest estimate is 180.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
82%
Hold
18%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GILD. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap365.43B
AbbVie competes directly with Gilead in the areas of hepatitis C treatments and is also a major player in immunology and oncology.
Merck
MRK
Mkt Cap277.02B
Merck & Co. offers competitive products in the antiviral space, including treatments for HIV and hepatitis C, directly challenging Gilead's core market.
Pfizer
PFE
Mkt Cap149.77B
Pfizer competes across several therapeutic areas including oncology, immunology, and antiviral drugs, overlapping with Gilead's product portfolio.
Bristol-Myers Squibb
BMY
Mkt Cap118.87B
Bristol Myers Squibb is a key competitor in the oncology and immunology sectors, areas where Gilead Sciences is actively expanding its presence.
Johnson & Johnson
JNJ
Mkt Cap546.9B
Johnson & Johnson, through its pharmaceutical segment Janssen, competes in the HIV and hepatitis C markets, among others, where Gilead has significant interests.
AMGEN
AMGN
Mkt Cap178B
Amgen competes with Gilead in the biopharmaceutical space, particularly in the areas of oncology and inflammatory diseases.
GSK
GSK
Mkt Cap103.01B
GlaxoSmithKline, through its ViiV Healthcare joint venture, is a strong competitor in the HIV treatment market, directly challenging Gilead's leadership.
Novartis
NVS
Mkt Cap279.67B
Novartis competes with Gilead in several areas including oncology and gene therapy, with both companies investing heavily in research and development.
Roche
RHHBY
Mkt Cap328.49B
Roche, through its Genentech unit, competes in the oncology and antiviral markets, areas where Gilead has key products.
Astrazeneca
AZN
Mkt Cap286.4B
AstraZeneca competes with Gilead in the oncology sector, with both companies developing treatments for various cancers.

About

There is no Profile data available for GIS.SG.
Show more...
CEO
Mr. Daniel P. O'Day
Employees
17600
Country
United States
ISIN
US3755581036

Listings

F
DE
GIS.F
TO
CA
GILD.TO
F
DE
GIS0.F
LSE
GB
0QYQ.LSE

1 Comments

toosie

looks like a good buy

1

FAQ

What is Gilead Sciences stock price today?▼
The current price of GILD is $133.48 USD — it has increased by +0.56% in the past 24 hours. Watch Gilead Sciences stock price performance more closely on the chart.
What is Gilead Sciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gilead Sciences stocks are traded under the ticker GILD.
Is Gilead Sciences stock price growing?▼
GILD stock has risen by +3.6% compared to the previous week, the month change is a -4.75% fall, over the last year Gilead Sciences has showed a +36.37% increase.
What is Gilead Sciences market cap?▼
Today Gilead Sciences has the market capitalization of 165.7B
When is the next Gilead Sciences earnings date?▼
Gilead Sciences is going to release the next earnings report on May 07, 2026.
What were Gilead Sciences earnings last quarter?▼
GILD earnings for the last quarter are 1.86 USD per share, whereas the estimation was 1.81 USD resulting in a +2.76% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Gilead Sciences revenue for the last year?▼
Gilead Sciences revenue for the last year amounts to 58.89B USD.
What is Gilead Sciences net income for the last year?▼
GILD net income for the last year is 17.02B USD.
Does Gilead Sciences pay dividends?▼
Yes, GILD dividends are paid quarterly. The last dividend per share was 0.82 USD. As of today, Dividend Yield (FWD)% is 2.46%.
How many employees does Gilead Sciences have?▼
As of May 06, 2026, the company has 17,600 employees.
In which sector is Gilead Sciences located?▼
Gilead Sciences operates in the Health & Wellness sector.
When did Gilead Sciences complete a stock split?▼
The last stock split for Gilead Sciences was on January 28, 2013 with a ratio of 2:1.
Where is Gilead Sciences headquartered?▼
Gilead Sciences is headquartered in Foster City, United States.